社区人群中阿尔茨海默病血液生物标志物与脑结构变化模式
研究纳入361名来自瑞典人群研究的无痴呆老年人(简易智力状态检查评分≥27且无既往脑血管事件),基线检测血液磷酸化tau217、神经丝轻链和胶质纤维酸性蛋白,基线及第3和/或6年行脑磁共振成像,分析生物标志物与脑体积及脑小血管病负荷变化的关系。结果显示较高的磷酸化tau217与海马和杏仁核体积下降更快相关,升高的胶质纤维酸性蛋白与全脑组织体积下降、脑室扩大和海马萎缩相关,较高的神经丝轻链与全脑组织体积下降、脑室扩大、海马和杏仁核萎缩及白质高信号累积更快相关。
要点
- 在无认知损害的社区老年人中,较高的血液磷酸化tau217与海马和杏仁核萎缩更快相关。
- 升高的胶质纤维酸性蛋白与全脑组织体积下降、脑室扩大和海马萎缩相关。
- 较高的神经丝轻链与更广泛的脑萎缩及白质高信号累积更快相关。
核心结论
- 在认知未受损的老年人中,升高的血液磷酸化tau217与阿尔茨海默病特异性脑区萎缩更快相关,而神经丝轻链和胶质纤维酸性蛋白与更广泛的萎缩相关,神经丝轻链还与白质高信号累积加速相关。
- 这些发现提示阿尔茨海默病相关血液生物标志物可能在早期阶段即捕捉到不同的痴呆相关脑结构变化。
研究设计与样本
- 研究纳入361名来自瑞典人群研究的无痴呆参与者,简易智力状态检查评分≥27且无既往脑血管事件。
- 基线检测血液磷酸化tau217、神经丝轻链和胶质纤维酸性蛋白,基线及第3和/或6年行脑磁共振成像。
- 采用线性混合模型分析阿尔茨海默病相关血液生物标志物与全脑组织体积、侧脑室、海马、杏仁核及白质高信号体积变化之间的关联。
主要发现
- 随访期间,较高的磷酸化tau217与海马体积下降更快相关(β*year = −0.047,95% CI = −0.077至−0.018),并与杏仁核体积下降更快相关(β*year = −0.064,95% CI = −0.105至−0.022)。
- 升高的胶质纤维酸性蛋白与全脑组织体积下降更快相关(β*year = −0.040,95% CI = −0.059至−0.021),与脑室扩大相关(β*year = 0.028,95% CI = 0.013至0.042),并与海马萎缩相关(β*year = −0.038,95% CI = −0.064至−0.013)。
- 较高的神经丝轻链与全脑组织体积下降更陡、脑室扩大、海马和杏仁核萎缩及白质高信号累积更快相关。
- 排除基线时轻度认知损害的参与者后,结果基本保持一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective We aimed to investigate the associations between Alzheimer's disease (AD)-related blood biomarkers and changes in brain volumes and cerebrovascular burden in community-dwelling older adults. Methods We included 361 dementia-free participants with a Mini-Mental State Examination (MMSE) score ≥ 27 and without prior cerebrovascular events from a Swedish population-based study. Blood phosphorylated-tau217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured at baseline. Brain magnetic resonance imaging (MRI) was performed at baseline and after 3 and/or 6 years. Linear mixed models were used to examine associations between AD-related blood biomarkers and changes in volumes of total brain tissue (TBTV), lateral ventricles, hippocampus, amygdala, and white matter hyperintensities (WMHs). Results During the follow-up, higher p-tau217 was associated with faster volume loss in the hippocampus (β*year = −0.047, 95% confidence interval [CI] = −0.077 to −0.018) and in the amygdala (β*year = −0.064, 95% CI = −0.105 to −0.022). Elevated GFAP was linked to faster TBTV decline (β*year = −0.040, 95% CI = −0.059 to −0.021), ventricular enlargement (β*year = 0.028, 95% CI = 0.013 to 0.042), and hippocampal shrinkage (β*year = −0.038, 95% CI = −0.064 to −0.013). Participants with higher NfL showed steeper TBTV decline, ventricular enlargement, hippocampal and amygdala shrinkage, and faster WMH accumulation. Results remained largely consistent after excluding participants with mild cognitive impairment at baseline. Interpretation In cognitively unimpaired older adults, elevated blood p-tau217 was linked to faster shrinkage in AD-specific brain regions, whereas NfL and GFAP were associated with more widespread atrophy, with NfL also associated with accelerated WMH accumulation. These findings suggest that AD-related blood biomarkers may capture different dementia-related structural brain changes already at early stages. ANN NEUROL 2026;100:987–997
引用
- Annals of Neurology:Blood Biomarkers of Alzheimer's Disease and Patterns of Structural Brain Changes in the Community
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。